Hepatis C virus genotype 4

Autor:	Ossama A, Shobokshi
Rok vydání:	2003
Předmět:	Male Clinical Trials as Topic Dose-Response Relationship Drug Genotype Saudi Arabia Interferon-alpha Genome Viral Hepacivirus Hepatitis C Chronic Interferon alpha-2 Prognosis Drug Administration Schedule Recombinant Proteins Treatment Outcome Ribavirin Humans Drug Therapy Combination Female
Zdroj:	Saudi medical journal. 24
ISSN:	0379-5284
Popis:	Hepatitis C virus genotype 4 chronic hepatitis predominates in the Eastern Mediterranean region of the world. In the Kingdom of Saudi Arabia, as high as 62% of all cases are due to genotype 4. Results of efficacy and safety clinical trials using pegylated-interferon plus ribavirin for chronic hepatitis C patients have shown great promise, but treatment of early responders should be maintained at 180 mg of pegylated-interferon alfa-2a plus 1000-1200 mg of ribavirin for 48 weeks unlike the 24 weeks recommended for genotypes 2 and 3. Hepatitis C genotype 4 may not be as "difficult to treat" as initially thought.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::9fde9c93e96ecaacbd18c06beb9fca6f https://pubmed.ncbi.nlm.nih.gov/12897906 Zobrazit plný text záznamu